Complete Cytogenetic Response, Not Deep Molecular Response, Is Associated With Survival in Chronic Myeloid Leukemia Reply

被引：2
|
作者：
Hehlmann, Ruediger [1 ]
Hasford, Joerg [2 ]
Pfirrmann, Markus [2 ]
Lauseker, Michael [2 ]
Saussele, Susanne [1 ]
Hochhaus, Andreas [3 ]
机构：
[1] Heidelberg Univ, Univ Med Mannheim, Mannheim, Germany
[2] Univ Munich, Inst Med Informat Verarbeitung Biomet & Epidemiol, Munich, Germany
[3] Univ Klinkum Jena, Jena, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 27期
关键词：
KINASE INHIBITOR THERAPY; RECOMMENDATIONS; IMATINIB;
D O I：
10.1200/JCO.2014.56.3908
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3078 / +
页数：2
相关论文
共 50 条
  • [41] Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
    Li, Zongru
    Zhang, Xiaoshuai
    Zhao, Yijing
    Lu, Linping
    Guo, Yong
    Gale, Robert Peter
    Qin, Yazhen
    Jiang, Qian
    CANCER, 2025, 131 (01)
  • [42] Performance of Sokal and Eutos Scores for Predicting Cytogenetic and Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia-Chronic Phase Patients on Imatinib
    Sandip Ganguly
    K. C. Lakshmaiah
    Linu Abraham Jacob
    Suresh Babu
    Lokanatha Dasappa
    K. S. Govind Babu
    Indian Journal of Hematology and Blood Transfusion, 2017, 33 : 82 - 86
  • [43] Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors
    Cayssials, Emilie
    Tartarin, Florence
    Guilhot, Joelle
    Sorel, Nathalie
    Chomel, Jean Claude
    Leleu, Xavier
    Guilhot, Francois
    LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 766 - 769
  • [44] Early and sustained deep molecular response achieved with nilotinib in high Sokal risk chronic myeloid leukemia patients
    Zaidi, Uzma
    Kaleem, Bushra
    Borhany, Munira
    Maqsood, Sidra
    Fatima, Naveena
    Sufaida, Gul
    Ansari, Saqib Hussain
    Farzana, Tasneem
    Shamsi, Tahir Sultan
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 1493 - 1502
  • [45] Failure of treatment-free remission after a prolonged deep molecular response in patients with chronic myeloid leukemia
    Nasnas, Patrice E.
    Jabbour, Elias J.
    Sasaki, Koji
    Issa, Ghayas C.
    Masarova, Lucia
    Short, Nicholas J.
    Haddad, Fadi G.
    ACTA HAEMATOLOGICA, 2024, : 105 - 110
  • [46] Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors
    Aoki, Jun
    Ohashi, Kazuteru
    Kobayashi, Takeshi
    Kakihana, Kazuhiko
    Hirashima, Yuka
    Sakamaki, Hisashi
    LEUKEMIA & LYMPHOMA, 2012, 53 (07) : 1412 - 1414
  • [47] Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia
    Zheng, Qiaoli
    Cao, Jiang
    Hamad, Nada
    Kim, Hyeoung-Joon
    Moon, Joon Ho
    Sohn, Sang Kyun
    Jung, Chul Won
    Lipton, Jeffrey H.
    Kim, Dennis Dong Hwan
    JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
  • [48] Molecular monitoring of chronic myeloid leukemia: a personalized approach to optimizing treatment response
    Nichols, Linda
    Pippnis, Julie
    Castle, Lon
    Cassler, Mary
    Fuller, Courtney
    PERSONALIZED MEDICINE, 2012, 9 (07) : 727 - 737
  • [49] Complete Cytogenetic Response and Major Molecular Response as Surrogate Outcomes for Overall Survival in First-Line Treatment of Chronic Myelogenous Leukemia: A Case Study for Technology Appraisal on the Basis of Surrogate Outcomes Evidence
    Oriana, Ciani
    Martin, Hoyle
    Toby, Pavey
    Chris, Cooper
    Ruth, Garside
    Claudius, Rudin
    Rod, Taylor
    VALUE IN HEALTH, 2013, 16 (06) : 1081 - 1090
  • [50] Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
    Latagliata, Roberto
    Romano, Angela
    Mancini, Marco
    Breccia, Massimo
    Carmosino, Ida
    Vozella, Federico
    Montagna, Chiara
    Volpicelli, Paola
    De Angelis, Federico
    Petrucci, Luigi
    Serrao, Alessandra
    Molica, Matteo
    Salaroli, Adriano
    Diverio, Daniela
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2016, 57 (01) : 99 - 102
12345